N-type calcium channel blockers in pain and stroke

Bibliography

• MCCLESKEY E: Calcium channels: cellular roles and molecular mechanisms. Curr. Opin. Neurobiol (1994) 4:304–312.
   PubMedGoogle Scholar
• ••A review with 58 references on cellular calcium channelsand their functions is presented.
   Google Scholar
• DENYER J, WORLEY J, COX B et al.: HTS approaches to voltage-gated ion channel drug discovery. Drug Disc. Today (1998) 3(7):323–332.
   Web of Science ®Google Scholar
• RANDALL AD, TSIEN RW: Contrasting biophysical and pharmacological properties of T-type and R-type cal-cium channels. Neuropharmacology (1997) 36(7)879–893.
   Google Scholar
• TSIEN RW: Key clockwork component cloned. Nature (1998) 391 (6670):839–841.
   PubMed Web of Science ®Google Scholar
• OLIVERA BM, CRUZ LJ, DE SANTOS V et al: Neuronal cal-cium channel antagonists. Discrimination between calcium channel subtypes using w-conotoxin from Conus magus venom. Biochemistry (1987) 26(8)2086–2090.
   Google Scholar
• KOHNO T, KIM JI, KOBAYASHI K et al.: Three-dimensional structure in solution of the calcium chan-nel blocker omega-conotoxin MVIIA. Biochemistry (1995) 34 (32) :10256–10265.
   PubMed Web of Science ®Google Scholar
• BASUS VJ, NADASDI L, RAMACHANDRAN J, MILJANICHGP: Solution structure of omega-conotoxin MVIIA us-ing 2D NMR spectroscopy. FEBS Lett. (1995) 370 (3) :163–169.
   PubMedGoogle Scholar
• KIM JI, TAKAHASHI M, OHTAKE A et al.: Tyr13 is essentialfor the activity of omega-conotoxin MVIIA and GVIA, specific N-type calcium channel blocker. Biochem. Bio-phys. Res. Commun. (1995) 206 (2) :449–454.
   PubMed Web of Science ®Google Scholar
• NADASDI L, YAMASHIRO D, CHUNG D: Structure-activity analysis of a Conus peptide blocker of N-Type neuronal calcium channels. Biochemistry (1995) 34(25):8076–8081.
   PubMed Web of Science ®Google Scholar
• BOWERSOX S, TICH N, MAYO M, LUTHER R: SNX-111. Antinociceptive agent. N-type voltage-sensitive cal-cium channel blocker. Drugs Fut. (1998) 23(2)152–160.
   Google Scholar
• ••A detailed review of the analgesic, toxicological and clinicalstudies on SNX-111.
   Google Scholar
• MALMBERG AB, YAKSH TL: Effect of continuous in-trathecal infusion of w-conopeptides, N-type calcium-channel blockers, on behaviour and antinociception in the formalin and hot-plate tests in rats. Pain (1995) 60(1)83–90.
   Google Scholar
• BOWERSOX S, GADBOIS, T, SINGH T et al.: Selective N-type neuronal voltage-sensitive calcium channel blocker, SNX-111, produces spinal antinociception in rat models of acute, persistent and neuropathic pain. J. Pharmacol. Exp. Ther. (1996) 279(3):1243–1249.
   PubMed Web of Science ®Google Scholar
• Ziconotide. IDdb drug report. Current Drugs Ltd. (1998).
   Google Scholar
• •Excellent review on all aspects of the development of SNX-111.
   Google Scholar
• Neurex to file ziconotide NDA (new drug application) this year. Scrip (1998).
   Google Scholar
• VALENTINO K, NEWCOMB R, GADBOIS T et al.: A selec-tive N-type calcium channel antagonist protects against neuronal loss after global cerebral ischemia. Proc. Natl. Acad. Sci. USA (1993) 90(16):7894–7897.
   PubMed Web of Science ®Google Scholar
• ZHAO Q, SMITH M-L, SIESJOE BK: The w-conopeptide SNX-111, an N-type calcium channel blocker, dramati-cally ameliorates brain damage due to transient focal ischemia. Acta Physiol. Scand. (1994) 150(4) :459–461.
   PubMedGoogle Scholar
• MCGUIRE D, BOWERSOX S, FELLMANN JD, LUTHER RR: Sympatholysis after neuron-specific, N-type, voltage-sensitive calcium channel blockade: first demonstra-tion of N-channel function in humans. J. Cardiovasc. Pharmacol. (1997) 30(3)400–403.
   Google Scholar
• BOWERSOX SS, SINGH T, NADASDI L et al: Cardiovascu-lar effects of w-conopeptides in conscious rats: mecha-nisms of action. J. Cardiovasc. Pharmacol (1992) 20(5)756–764.
   Google Scholar
• UN Z, HAUS J, EDGERTON J, LIPSCOMBE D: Identifica-tion of functionally distinct isoforms of the N-type Ca2+ channel in rat sympathetic ganglia and brain. Neuron (1997) 18(1):153–166.
   PubMed Web of Science ®Google Scholar
• UNEYAMA H, TAKAHARA A, DOHMOTO H et al.: Block-ade of N-type Ca2+ current by cilnidipine (FRC-8653) in acutely dissociated rat sympathetic neurons. Br. J. Pharmacol. (1997) 122(1):37–42.
   PubMed Web of Science ®Google Scholar
• COHAN SL, REDMOND DJ, CHEN M et al.: Flunarizine blocks elevation of free cytosolic calcium in synapto-somes following sustained depolarization. J. Cereb. Blood Flow Metab. (1993) 13(6):947–954.
   PubMed Web of Science ®Google Scholar
• COHAN SL, CHEN M, REDMOND D, WILSON D: Depolarization-induced presynaptic calcium accumu-lation may occur by an N-type channel that is blocked by flunarizine. Ann. NY Acad. Sci. (1991) 635:397–399.
   PubMed Web of Science ®Google Scholar
• ITO C, IM WB, TAKAGI H et al: U-92032, a T-type Ca2+channel blocker and antioxidant, reduces neuronal ischemic injuries. Eur. j Pharmacol. (1994) 257(3)203–210.
   Google Scholar
• NOMURA Y, YAMAKAWA T, NISHIOKA K et al.: Synthesisand structure-activity relationships of 244-benzhydry1-1-piperaziny1)-1-phenylethanols as new calcium blockers. Chem. Pharm. Bull. (1995) 43(2)241–246.
   Google Scholar
• AKAIKE N, ISHIBASHI H, HARA H etal. Effect of KB-2796, a new diphenylpiperazine Ca2+ antagonist, on voltage-dependent Ca2+ currents and oxidative me-tabolism in dissociated mammalian CNS neurons. Brain Res. (1993) 619(1–2):263–270.
   Google Scholar
• TERRIAN DM, DAMRON DS, DORMAN RV, GANNON RL:Effects of calcium antagonists on the evoked release of dynorphin A(1-8) and availability of intraterminal cal-cium in rat hippocampal mossy fiber synaptosomes. Neurosci. Lett. (1989) 106(3):322–327.
   PubMed Web of Science ®Google Scholar
• MATSUI Y, YAMAGAMI I, HIRAI K: Comparison of thecalcium entry and calcium overload blocking proper-ties of R71811 and flunarizine. Naunyn-Schmiedeberg's Arch. Pharmacol. (1990) 342(3):264–270.
   Google Scholar
• BROWN CM, RUSH WR, COLQUHOUN HA: Lifarizine: ablocker of inactivated voltage-dependent sodium channels and calcium channels with cerebral neuro-protective action. CNS Drug Rev. (1995) 1(2):149–167.
   Google Scholar
• BUDD DC, MAY GR, NICHOLLS DG, MCCORMACK JG: In-hibition by lifarizine of intracellular Ca2+ rises and glu-tamate exocytosis in depolarized rat cerebrocortical synaptosomes and cultured neurons. Br. J. Pharmacol (1996) 118(1):162–166.
   PubMed Web of Science ®Google Scholar
• XU X, LEE KS: A selective blocker for rested T-type Ca2+ channels in guinea pig atrial cells. J. Pharmacol Exp. Ther. (1994) 268(3):1135–1142.
   PubMed Web of Science ®Google Scholar
• AVERY RB, JOHNSTON D: Ca2+ Channel antagonist U-92032 inhibits both T-type Ca2+ channels and Na+ channels in hippocampal CA1 pyramidal neurons. J. Neurophysiol (1997) 77(2)1023–1028.
   Google Scholar
• FUJII S, KAMEYAMA K, HOSONO M et al.: Effect of cil-nidipine, a novel dihydropyridine Ca2±-channel an-tagonist, on N-type Ca2+ channel in rat dorsal root ganglion neurons. J. Pharmacol. Exp. Ther. (1997) 280(3) :1184–1191.
   PubMedGoogle Scholar
• CLEMENTI E, MARTINI A, STEFANI G et al.: LU52396, aninhibitor of the store-dependent (capacitative) Ca2+ in-flux. Eur. J. Pharmacol Mol. Pharmacol. Sect. (1995) 289(1):23–31.
   PubMed Web of Science ®Google Scholar
• GEER JJ, DOOLEY DJ, ADAMS ME: Potassium ion-stimulated calcium-45 ion flux into rat neocortical mini-slices is blocked by co-Aga-IVA and the dual so-dium/calcium channel blockers lidoflazine and flu-narizine. Neurosci. Lett. (1993) 158(1)97–100.
   Google Scholar
• GRANTHAM CJ, MAIN MJ, CANNELL MB: Fluspirileneblock of N-type calcium current in NGF-differentiated PC12 cells. Br. J. Pharmacol (1994) 111(2):483–488.
   PubMed Web of Science ®Google Scholar
• SAH DW, BEAN BP: Inhibition of P-type and N-type cal-cium channels by dopamine receptor antagonists. Mol. Pharmacol. (1994) 45(0:84–92.
   PubMedGoogle Scholar
• BENHAM CD, BROWN TH, COOPER DG et al.: SB 201823-A, a neuronal calcium antagonist is neuropro-tective in two models of cerebral ischemia. Neurophar-macology (1993) 32(10:1249–1257.
   PubMedGoogle Scholar
• WOOD NI, BARONE FC, BENHAM CD et al: The effects ofSB 206284A, a novel neuronal calcium-channel an-tagonist, in models of cerebral ischemia. J. Cereb. Blood Flow Metab. (1997) 17(4):421–429.
   PubMed Web of Science ®Google Scholar
• BARONE FC, LYSKO PG, PRICE WJ et al.: SB 201823-A an-tagonizes calcium currents in central neurons and re-duces the effects of focal ischemia in rats and mice. Stroke (Dallas) (1995) 26(9):1683–1689.
   PubMedGoogle Scholar
• O'NEILL MJ, BATH CP, DELL CP et al.: Effects of Ca2+ and Na + channel inhibitors in vitro and in global cerebral ischemia in vivo. Eur. J. Pharmacol. (1997) 332 (2):121–131.
   Google Scholar
• BATH CP, FARRELL LN, GILMORE J et al.: The effects of ifenprodil and eliprodil on voltage-dependent Ca2+ channels and in gerbil global cerebral ischemia. Eur. J. Pharmacol. (1996) 299(1-3):103–112.
   PubMed Web of Science ®Google Scholar
• SIPAHIMALANI AS, WERTH JL, MICHELSON RH et al.: Lipo-philic amino alcohols with calcium channel blocking activity. Biochem. Pharmacol (1992) 44(10):2039–2046.
   PubMed Web of Science ®Google Scholar
• VARMING T, CHRISTOPHERSEN P, MOELLER A et al: Syn-thesis and biological activity of the neuronal calcium channel blocker 2-amino-1-(2,5-dimethoxypheny0-5-trifluoromethyl benzimidazole (NS-649). Bioorg. Med. Chem. Lett. (1996) 6(3):245–248.
   Web of Science ®Google Scholar
• Neurosearch, company communication. December (1995).
   Google Scholar
• MALONE TC, DOOLEY D, LESCOSKY LJ et al.: Synthesis and biological evaluation of substituted methylene bis-(8-quinolol) derivatives as N-type calcium channel blockers. 214th ACS Meeting. Las Vegas, USA (1997). MEDI–006.
   Google Scholar
• YUEN P-W, SCHELKUN RM, SZOKE B et al.: Synthesis andstructure activity relationship of substituted quinoline and isoquinoline derivatives as N-type calcium chan-nel blockers. 214th ACS Meeting. Las Vegas, USA (1997). MEDI–005.
   Google Scholar
• YUEN P-W, SCHELKUN RM, MALONE TC et al.: Synthesisand biological activity of substituted bis-(4-hydroxypheny0 methanes as N-type calcium channel blockers. 214th ACS Meeting. Las Vegas, USA (1997). MEDI–007.
   Google Scholar
• TUPPER DE, AMBLER SJ, BLEAKMAN D et al.: Novel an-tagonists of neuronal (non-L-type) voltage-dependent calcium channels. 27th Annual Society for Neuroscience Meeting. New Orleans, USA (1997). 472.1.
   Google Scholar
• ROMEY G, LAZDUNSKI M: Effects of a new class of cal-cium antagonists, SR33557 (fantofarone) and 5R33805, on neuronal voltage-activated Ca2+ channels. Pharmacol Exp. Ther. (1994) 271(3):1348–1352.
   PubMed Web of Science ®Google Scholar
• MORISHITA T, SATO A, HISAMOTO M et al.: N-type cal-cium channel blockers from a marine bacterium, Cy-tophaga sp. SANK 71996. J. Antibiot. (1997) 50(6):457–468.
   Google Scholar
• BLEAKMAN D, BOOT JR, DELL C et al.: Novel antagonists of neuronal (non-L-type) voltage-dependent calcium channels. 15th European Federation of Medicinal Chemis-by International Symposium on Medicinal Chemistry. Edin-burgh (1998) P133.
   Google Scholar
• HISAMOTO M, INAOKA Y, SAKAIDA Y et al.: A-53930 Aand B, novel N-type Ca2+ channel blockers. J. Antibiot. (1998) 51(7):607–617.
   PubMed Web of Science ®Google Scholar